Loading...
MoonLake Immunotherapeutics
MLTX•NASDAQ
Healthcare
Biotechnology
$55.07
$0.04(0.07%)
MoonLake Immunotherapeutics (MLTX) Financial Performance & Income Statement Overview
Review MoonLake Immunotherapeutics’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
100.00%
↑ 100.00%
Net Income Growth
-335054.64%
↓ 335054.64%
Operating Cash Flow Growth
-172.54%
↓ 172.54%
Operating Margin
-121031.50%
↓ 121031.50%
Gross Margin
22.40%
↑ 22.40%
Net Profit Margin
-142871.73%
↓ 142871.73%
ROE
-31.24%
↓ 31.24%
ROIC
-25.30%
↓ 25.30%
MoonLake Immunotherapeutics (MLTX) Income Statement & Financial Overview
Review MoonLake Immunotherapeutics's (MLTX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $101850.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $50925.00 | $0.00 | $28112.00 | $22813.00 |
| Gross Profit | $50925.00 | $0.00 | -$28112.00 | -$22813.00 |
| Gross Profit Ratio | $0.50 | $0.00 | ||
| R&D Expenses | $39.06M | $35.74M | $23.63M | $12.99M |
| SG&A Expenses | $9.22M | $7.38M | $6.92M | $6.81M |
| Operating Expenses | $48.28M | $43.11M | $30.55M | $19.80M |
| Total Costs & Expenses | -$49.58M | $43.11M | $30.58M | $19.82M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.30M | $32515.00 | $28112.00 | $22813.00 |
| EBITDA | -$45.05M | -$43.08M | -$30.55M | -$19.80M |
| EBITDA Ratio | -$442.35 | |||
| Operating Income | -$49.58M | -$43.11M | -$30.58M | -$19.82M |
| Operating Income Ratio | -$486.80 | |||
| Other Income/Expenses (Net) | $3.23M | $7.09M | $5.90M | $5.92M |
| Income Before Tax | -$46.35M | -$36.02M | -$24.68M | -$13.91M |
| Income Before Tax Ratio | -$455.13 | |||
| Income Tax Expense | $41140.00 | $92106.00 | $78701.00 | $70252.00 |
| Net Income | -$45.60M | -$35.39M | -$24.27M | -$13.67M |
| Net Income Ratio | -$447.76 | |||
| EPS | -$0.72 | -$0.56 | -$0.39 | -$0.22 |
| Diluted EPS | -$0.72 | -$0.56 | -$0.39 | -$0.22 |
| Weighted Avg Shares Outstanding | $63.07M | $62.90M | $62.87M | $62.64M |
| Weighted Avg Shares Outstanding (Diluted) | $63.07M | $62.90M | $62.87M | $62.64M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan